GeneDx (WGS) announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, an initiative establishing the nation’s first state-backed genomic newborn screening program. The Sunshine Genetics program, a five-year pilot program, will offer whole-genome sequencing for newborns at select academic medical centers and hospitals, providing families and clinicians the opportunity for early detection and diagnosis of rare diseases. Under the Sunshine Genetics Act, Florida becomes the first state to offer genomic newborn screening for hundreds of diseases, marking a historic expansion from research to the standard of care. The program’s goal is to sequence 100,000 newborns.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others
- GeneDx appoints Gurry as Chief Business Officer
- Eli Lilly’s (LLY) AI Chief Joins the Board of GeneDx
- GeneDx Holdings Appoints Thomas Fuchs to Board
- GeneDx price target raised to $140 from $120 at Piper Sandler